SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
General issues related to Buy American/American First; and issues related to North American Free Trade Agreement.
Foreign entity interest: Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACOB ANDREW HARTSFIELD | — |
| FRANCIS JOGUES RIENZO | — |
Economics/Economic Development ECN
Issues related to site expansions.
Foreign entity interest: Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY L REDL | — |
Taxation/Internal Revenue Code TAX
H.R. 394 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications; S.85 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Copyright/Patent/Trademark CPT
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| SARA FROELICH | — |
| ADAM GLUCK | — |
| AMY L REDL | — |
Health Issues HCR
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| SARA FROELICH | — |
| ADAM GLUCK | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.